Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) EBITDA Margin (2020 - 2023)

Candel Therapeutics' EBITDA Margin history spans 4 years, with the latest figure at 1533.14% for Q4 2023.

  • For Q4 2023, EBITDA Margin rose 2766862.0% year-over-year to 1533.14%; the TTM value through Dec 2023 reached 1479.42%, up 2948103.0%, while the annual FY2024 figure was 1596.7%, 307612.0% down from the prior year.
  • EBITDA Margin for Q4 2023 was 1533.14% at Candel Therapeutics, up from 1324.51% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 26600.0% in Q4 2021 and bottomed at 52135.48% in Q3 2021.
  • The 4-year median for EBITDA Margin is 16061.29% (2021), against an average of 13696.24%.
  • The largest annual shift saw EBITDA Margin soared 4635806bps in 2021 before it plummeted -5273548bps in 2022.
  • A 4-year view of EBITDA Margin shows it stood at 19758.06% in 2020, then soared by 235bps to 26600.0% in 2021, then tumbled by -198bps to 26135.48% in 2022, then surged by 106bps to 1533.14% in 2023.
  • Per Business Quant, the three most recent readings for CADL's EBITDA Margin are 1533.14% (Q4 2023), 1324.51% (Q3 2023), and 1487.42% (Q2 2023).